Get notified of page updates
Public Policy Priorities
Review some of FORCE's current legislative and regulatory policy priorities that impact the hereditary cancer community.

Stay up to date on research and information

Sign Up for FORCE Newsletters

Policy Archive

Support Broader Access to Genetic Counseling

Genetic Counseling & Testing

January 2023 - With the start of a new congress, all legislation that didn't pass last year needs to be reintroduced. Stay tuned for updates on this legislation in the coming months...

Genetic counselors provide crucial information and expertise to anyone impacted by hereditary cancer. But, did you know that these knowledgeable providers are not approved Medicare practitioners? The Access to Genetic Counselor Services Act (H.R. 2144/S. 1450) aims to remedy this issue. Join FORCE and the National Society of Genetic Counselors to support coverage of genetic counseling for Medicare beneficiaries and expanded access to genetic counseling services.

Genetic Counseling PhotoGenetic testing is an increasingly important and complex service that improves health care by enabling informed medical decisions. Genetic counselors are professionals with advanced training in medical genetics and counseling to interpret genetic test results, and to guide and support patients, their families, and their healthcare team(s). Unfortunately, current Medicare policy restricts access to these highly trained providers who can optimize the benefits of genetic testing.

Many private health plans and state Medicaid programs look to Medicare for guidance on what health services should be covered. As such, this legislation is also likely to improve access and coverage of genetic counseling beyond Medicare.

Contact your elected officials and let them know why access to genetic counseling is important!

Take Action Now Become an Advocate 2024 Priorities Federal Policy State Policy Advocacy Archive

News Briefs

4/3/2024 - Submitted comments to Senator Cassidy and the HELP Committee in response to an RFI regarding oversight of clinical diagnostic tests, known as in vitro diagnostics (IVDs) and laboratory-developed tests (LDTs).

3/15/2024 - Joined the Coalition to Increase Access to Cancer Care (CIACC) in comments to House leadership on efforts to strengthen the Employee Retirement Income Security Act (ERISA) and emphasize the need to pass the Cancer Drug Parity Act.

3/1/2024 - Provided feedback to CMS on the Medicare Advantage Advanced Notice and accompanying Part D Redesign Program provisions aimed at reducing and managing beneficiary out-of-pocket costs in the Medicare Part D program.

2/29/2024 - Wrote sponsors to endorse the BENEFIT Act, which would require the FDA to include in the benefit-risk assessment framework of a new drug application how patient experience data was considered in the review process.

More